Drug Discovery & Development | Sovaldi Continues to Excel in Trials with Hep C, Advanced Liver Disease Drug Discovery & Development Study GS-US-334-0126 was a single-arm open-label Phase 2 trial in which patients with established recurrent HCV infection following liver transplantation received up to 24 weeks of therapy with Sovaldi plus RBV (escalating doses starting at 400 mg/day). New data reveals positive outcomes for hepatitis C transplant patients |
